ArticlebioRxiv : the preprint server for biology2026
Discovery of Selective Small-Molecule Ligands of SV2C by AI-Enhanced Virtual Screening and Experimental Validation.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Synaptic vesicle glycoprotein 2C (SV2C) is enriched in dopaminergic neurons and implicated in Parkinson's disease, but no selective small-molecule probes exist for it. Lacking a full-length SV2C structure, we built a homology model from SV2A cryo-EM templates and used molecular dynamics to characterize its conformational landscape. An AI-enhanced virtual screening pipeline, validated on a curated SV2A benchmark, was applied to 5.96 million commercial compounds, prioritizing 94 candidates for experimental testing. Of 71 compounds tested in an orthogonal biophysical assay cascade, 22 were active (31% hit rate), and five advanced to isoform-selectivity profiling. Compounds 36 and 56 emerged as leads, with SV2C
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.